Viking Therapeutics Stock Takes a Hit as Weight-Loss Pill Trial Shows High Dropout

Viking Therapeutics (VKTX) experienced a significant drop in its stock value, falling by over 40% following the disappointing results from its phase 2 weight-loss pill trial. The company’s stock plummeted by 41.68% on a Tuesday, reflecting investor concern over the high dropout rate in the study and the associated gastrointestinal side effects reported by many participants. Despite promising weight-loss results, Viking’s trial exposed serious challenges that have raised questions about the pill’s long-term viability and market potential.